Bladder Cancer

When it comes to bladder cancer, PD-1 and PD-L1 agents will become the new mainstay, says Jonathan E. Rosenberg, M.D.

According to results from a recent study, Keytruda had longer overall survival (OS) when compared to chemotherapy for patients with bladder cancer.

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected.

Geoffrey Sklar, M.D. talks about the successes of immunotherapy agents like Opdivo, and where this research is moving in the field of bladder cancer.

Opdivo had positive results in patients with advanced bladder cancer according to findings from the CheckMate-275 trial.

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Treating bladder cancer with a cystectomy may bring about some complicated side effects. Here are some resources to help.

CURE gathered some need-to-know facts about bladder cancer, the sixth most common cancer.

For decades, research into bladder cancer treatments was stagnant, but now science has moved into a period rife with new approaches — immunotherapy chief among them.

After the bladder is surgically removed and the urinary system diverted, most can return to their usual activities.

Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

The FDA voted against approving Qapzola for treatment of some patients with bladder cancer.

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

After a long lapse in advancements for bladder cancer, the approval of Tecentriq is changing the field.

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

CURE spoke with Stanley Yap about how physicians can improve care for patients with muscle-invasive bladder cancer.

The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.

“Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo,” said Jean Viallet.

A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.

A recent phase 1 study shows promise for the treatment of bladder cancer.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.

Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.